Understanding Adverse Event Reporting in Cosmetics: A MoCRA Overview

The cosmetic industry has seen significant regulatory updates with the introduction of the Modernization of Cosmetics Regulation Act (MoCRA). Among these updates, the definitions and requirements around adverse events and serious adverse events stand out for their implications on consumer safety and manufacturer responsibilities.

What Constitutes an Adverse Event Under MoCRA?

An "Adverse Event," as specified by MoCRA, encompasses any negative health-related occurrence tied to the use of a cosmetic product. This broad definition underscores the importance of vigilance and responsiveness from cosmetic companies in monitoring and addressing any potential health issues related to their products.

Understanding Serious Adverse Events: A Closer Look

Serious Adverse Event: an adverse event that

  • (A) results in:

    • death;

    • a life-threatening experience;

    • inpatient hospitalization;

    • a persistent or significant disability or incapacity;

    • a congenital anomaly or birth defect;

    • an infection; or

    • significant disfigurement (including serious and persistent rashes, second- or third-degree burns, significant hair loss, or persistent or significant alteration of appearance), other than as intended under conditions of use that are customary or usual; or

  • (B) requires, based on reasonable medical judgment, a medical or surgical intervention to prevent an outcome described in (A) above.

The Role of the Responsible Person

A key provision in MoCRA is the identification of a "responsible person" for each cosmetic product on the market. This individual or entity is tasked with receiving reports of adverse events, a duty that encompasses managing communications via domestic address, phone number, or electronic contact information. If the responsible person receives medical or other information about the adverse event within 1 year of the initial report to FDA, they must submit this new information to FDA within 15 business days. FDA will also have access to adverse event reports during an inspection. The requirement for this information to appear on both the inner and outer containers of cosmetic products underscores the FDA's commitment to ensuring accessible channels for consumer reports.

Navigating Adverse Event Reporting

The act mandates that the responsible person report serious adverse events to the FDA within 15 business days of receipt, including a copy of the product's label. This process is not just about compliance; it's a critical component of post-market surveillance, enabling the detection of product issues that could lead to a public health concern or recall. Moreover, the requirement to submit any new and material medical information within a year of the initial report reinforces the ongoing nature of this surveillance.

Record Keeping: Beyond Compliance

 If certain conditions are met, FDA can access and copy certain records related to a cosmetic product, including safety records. MoCRA requires that records of adverse event reports be maintained for six years (three years for small businesses), a directive that extends FDA's oversight during inspections. Effective record-keeping facilitates not only regulatory compliance but also plays a pivotal role in identifying product trends, normalizing incidence rates, and enhancing consumer safety through post-market surveillance.

Preparedness for Mandatory Recalls

The act grants the FDA authority to mandate recalls for cosmetics that pose serious health risks. The classification of recalls into three classes based on the severity of health consequences further illustrates the spectrum of risks associated with cosmetic products. For industry stakeholders, preparedness for such recalls begins with a robust adverse event reporting and record-keeping system.

Inspections and Records Access

Under MoCRA, the FDA's authority to inspect cosmetic facilities and access records has been clarified and expanded. This includes access to adverse event records and, under certain conditions, to lists of ingredients contributing to serious adverse events. However, it's noteworthy that the FDA's inspection authority does not extend to financial or sales data, emphasizing the focus on product safety over commercial aspects.

Implementing a Proactive Adverse Event Reporting System

The intricacies of MoCRA's provisions on adverse event reporting underscore the necessity for cosmetic companies to establish comprehensive policies and procedures. These should include standard operating procedures for monitoring, investigating, and reporting adverse events, as well as mechanisms for updating policies in line with evolving requirements.

Ensuring Beauty and Safety: Navigating MoCRA Compliance with The Equity and Wellness Collaborative

The Modernization of Cosmetics Regulation Act (MoCRA) is a pivotal advancement for consumer safety within the cosmetics industry. By setting forth clear guidelines for adverse event and serious adverse event reporting, MoCRA underscores the importance of transparency, accountability, and proactive risk management. Understanding and adhering to these provisions is not merely a regulatory obligation—it is a cornerstone of maintaining consumer trust and ensuring public health.

At The Equity and Wellness Collaborative, we specialize in navigating the complexities of MoCRA compliance. Our expertise lies in recognizing, accessing, and accurately reporting adverse events to the FDA on behalf of our clients. Acting as the responsible person for your cosmetic products, we ensure that all adverse events are reported in compliance with FDA requirements, providing peace of mind that your products continue to meet the highest standards of safety and regulatory compliance.

By partnering with us, you leverage our deep understanding of adverse event reporting mechanisms and our commitment to consumer safety. The Equity and Wellness Collaborative is more than just a consultancy; we are your ally in the ever-evolving landscape of cosmetic regulation. Let us guide you through the intricacies of MoCRA compliance, ensuring that your products not only meet but exceed the expectations of safety, efficacy, and quality.

For more information on how The Equity and Wellness Collaborative can assist your company in fulfilling its MoCRA obligations and to safeguard your brand's reputation through comprehensive adverse event reporting, please contact us today.

Together, we can ensure that your products continue to bring beauty to the world, safely and responsibly.

Marcha Isabelle Chaudry

Marcha Isabelle Chaudry, a distinguished attorney with over a decade of experience, is the founder of the Equity and Wellness Collaborative (EWC), a consultancy at the forefront of public and consumer policy and advocacy within the beauty, aesthetic, and wellness industries. Her expertise encompasses a deep understanding of regulatory compliance, strategic business solutions, and a commitment to promoting ethical practices and consumer safety.

Next
Next

Decoding MoCRA: Small Business Exemptions and What They Entail